Elutia Inc. is a commercial-stage company, which has developed a portfolio of products using both human and porcine tissue. Its portfolio of products spans the Device Protection, Women’s Health and Cardiovascular markets. These products are primarily sold to healthcare providers or commercial partners. In Device Protection, it sells CanGaroo, a biological envelope, that is indicated for use with implantable electronic devices, including cardiac and neurostimulator devices. In Women’s Health, it has developed both patented and proprietary technologies, culminating in the creation of SimpliDerm, a biological matrix designed to leverage the inherent science of natural healing processes. In Cardiovascular, it sells its specialized porcine small intestine submucosa, which is also the tissue used to make CanGaroo, for use as an intracardiac and vascular patch, as well as for pericardial reconstruction. In addition, its TYKE product is designed for use in the neonatal patient population.
BörsenkürzelELUT
Name des UnternehmensElutia Inc
IPO-datumOct 08, 2020
CEODr. C. Randal (Randal) Mills, Ph.D.
Anzahl der mitarbeiter51
WertpapierartOrdinary Share
GeschäftsjahresendeOct 08
Addresse12510 Prosperity Drive
StadtSILVER SPRING
BörseNASDAQ Capital Market Consolidated
LandUnited States of America
Postleitzahl20904
Telefon12402471143
Websitehttps://elutia.com/
BörsenkürzelELUT
IPO-datumOct 08, 2020
CEODr. C. Randal (Randal) Mills, Ph.D.
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten